论文部分内容阅读
为了探讨国产尿激酶的合理用量，我们对发病≤6小时的AMI患者进行不同剂量静脉溶栓临床疗效对比。100万单位组33例、125万单位组32例、150万单位组40例和175万单位组22例。结果：梗塞有关的冠脉早期再通率100万、125万、150万和175万单位组分别为42．42％、46．88％、67．50％和72．73％。100万与125万单位组比较无显著差异，分别与150万和175万单位组比较有显著差异（P＜0．05）；125万分别与150万和175万单位组比较有显著差异（P＜0．05）；150万和175万单位组比较无显著差异。证明国产尿激酶静脉溶栓100万和125万单位剂量偏小。我们认为采用150万～175万单位为宜。
In order to explore the reasonable dosage of domestic urokinase, we compared the clinical efficacy of different doses of intravenous thrombolysis in patients with AMI ≤ 6 hours of onset. There were 33 cases with 1 million units, 32 cases with 1.25 million units, 40 cases with 1.5 million units and 22 cases with 1.75 million units. Results: The rates of infarction-related early coronary recanalization rates were 42.42%, 46.88%, 67.50% and 72.73% respectively for 1 million, 1.25 million, 1.5 million and 1.75 million unit groups. There was no significant difference between 1 million and 1.25 million units, respectively, with 1.5 million and 1.75 million units respectively (P <0.05). There were significant differences between 1.25 million and 1.5 million and 1.75 million units <0.05). There was no significant difference between 1.5 million and 1.75 million units. Prove domestic urokinase intravenous thrombolysis 1 million and 1.25 million unit dose is too small. We think that it should be 1.5 to 1.75 million units.